Laboratorios Farmaceuticos Rovi, S.A. (LABFF)
USD 90.61
(0.0%)
USD 90.61
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 40.1 Million EUR | 175.95% |
| 2022 | -52.8 Million EUR | -103.97% |
| 2021 | -25.89 Million EUR | -227.19% |
| 2020 | 20.35 Million EUR | 18.01% |
| 2019 | 17.25 Million EUR | 128.15% |
| 2018 | -61.28 Million EUR | -2515.73% |
| 2017 | 2.53 Million EUR | 133.45% |
| 2016 | -7.58 Million EUR | -156.07% |
| 2015 | 13.52 Million EUR | 40.39% |
| 2014 | 9.63 Million EUR | -16.77% |
| 2013 | 11.57 Million EUR | -46.91% |
| 2012 | 21.8 Million EUR | 364.46% |
| 2011 | -8.24 Million EUR | 46.96% |
| 2010 | -15.54 Million EUR | -1158.79% |
| 2009 | -1.23 Million EUR | -119.45% |
| 2008 | 6.34 Million EUR | 27.85% |
| 2007 | 4.96 Million EUR | 732.48% |
| 2006 | -785 Thousand EUR | 100.0% |
| 2005 | -278.39 Billion EUR | -77830.88% |
| 2004 | -357.23 Million EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 68.68 Million EUR | 71.27% |
| 2024 Q2 | 76.58 Million EUR | -164.9% |
| 2023 Q4 | 40.1 Million EUR | 450.97% |
| 2023 FY | 40.1 Million EUR | 175.95% |
| 2023 Q1 | -72.15 Million EUR | -36.64% |
| 2023 Q2 | -87.31 Million EUR | -21.0% |
| 2023 Q3 | 7.27 Million EUR | 108.34% |
| 2022 Q1 | -29.44 Million EUR | -13.73% |
| 2022 FY | -52.8 Million EUR | -103.97% |
| 2022 Q2 | -84.49 Million EUR | -186.98% |
| 2022 Q4 | -52.8 Million EUR | -119.86% |
| 2022 Q3 | -24.01 Million EUR | 71.58% |
| 2021 Q1 | 101 Thousand EUR | -99.5% |
| 2021 Q4 | -25.89 Million EUR | 64.08% |
| 2021 FY | -25.89 Million EUR | -227.19% |
| 2021 Q2 | -53.91 Million EUR | -53479.21% |
| 2021 Q3 | -72.06 Million EUR | -33.68% |
| 2020 FY | 20.35 Million EUR | 18.01% |
| 2020 Q4 | 20.35 Million EUR | -48.62% |
| 2020 Q3 | 39.61 Million EUR | -0.78% |
| 2020 Q2 | 39.92 Million EUR | 92.69% |
| 2020 Q1 | 20.72 Million EUR | 20.12% |
| 2019 Q4 | 17.25 Million EUR | 847.28% |
| 2019 Q1 | -20.55 Million EUR | 66.46% |
| 2019 FY | 17.25 Million EUR | 128.15% |
| 2019 Q2 | -17.6 Million EUR | 14.34% |
| 2019 Q3 | 1.82 Million EUR | 110.34% |
| 2018 FY | -61.28 Million EUR | -2515.73% |
| 2018 Q3 | 22.04 Million EUR | 308.41% |
| 2018 Q2 | -10.57 Million EUR | -826.94% |
| 2018 Q1 | 1.45 Million EUR | -42.65% |
| 2018 Q4 | -61.28 Million EUR | -378.02% |
| 2017 Q4 | 2.53 Million EUR | -13.5% |
| 2017 FY | 2.53 Million EUR | 133.45% |
| 2017 Q3 | 2.93 Million EUR | 158.81% |
| 2017 Q2 | -4.98 Million EUR | -237.08% |
| 2017 Q1 | 3.63 Million EUR | 147.97% |
| 2016 Q1 | 1.51 Million EUR | -88.82% |
| 2016 Q2 | -4.89 Million EUR | -423.48% |
| 2016 Q3 | -3.09 Million EUR | 36.74% |
| 2016 Q4 | -7.58 Million EUR | -145.12% |
| 2016 FY | -7.58 Million EUR | -156.07% |
| 2015 Q4 | 13.52 Million EUR | -27.16% |
| 2015 Q2 | 9.36 Million EUR | 15.83% |
| 2015 Q3 | 18.57 Million EUR | 98.31% |
| 2015 Q1 | 8.08 Million EUR | -16.1% |
| 2015 FY | 13.52 Million EUR | 40.39% |
| 2014 Q3 | 9.05 Million EUR | 181140.0% |
| 2014 Q2 | -5000.00 EUR | -100.03% |
| 2014 Q4 | 9.63 Million EUR | 6.44% |
| 2014 FY | 9.63 Million EUR | -16.77% |
| 2014 Q1 | 17.36 Million EUR | 49.97% |
| 2013 Q4 | 11.57 Million EUR | -19.95% |
| 2013 Q3 | 14.46 Million EUR | 49.2% |
| 2013 Q2 | 9.69 Million EUR | -39.02% |
| 2013 Q1 | 15.89 Million EUR | -27.1% |
| 2013 FY | 11.57 Million EUR | -46.91% |
| 2012 Q1 | 6.41 Million EUR | 177.76% |
| 2012 Q4 | 21.8 Million EUR | 29.08% |
| 2012 Q3 | 16.89 Million EUR | 151.61% |
| 2012 FY | 21.8 Million EUR | 364.46% |
| 2012 Q2 | -32.72 Million EUR | -610.48% |
| 2011 Q3 | -7.08 Million EUR | 20.16% |
| 2011 FY | -8.24 Million EUR | 46.96% |
| 2011 Q4 | -8.24 Million EUR | -16.36% |
| 2011 Q2 | -8.87 Million EUR | -231.4% |
| 2011 Q1 | 6.75 Million EUR | 143.45% |
| 2010 FY | -15.54 Million EUR | -1158.79% |
| 2010 Q4 | -15.54 Million EUR | 0.0% |
| 2009 FY | -1.23 Million EUR | -119.45% |
| 2008 FY | 6.34 Million EUR | 27.85% |
| 2007 FY | 4.96 Million EUR | 732.48% |
| 2006 FY | -785 Thousand EUR | 100.0% |
| 2005 FY | -278.39 Billion EUR | -77830.88% |
| 2004 FY | -357.23 Million EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | -154.425% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | -873.889% |
| SQZ Biotechnologies Company | -36.23 Million USD | 210.671% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 6.281% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 736.13% |
| Mesoblast Limited | 55.85 Million USD | 28.202% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | -4225.454% |
| Genus plc | 190.6 Million USD | 78.959% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | -1693.739% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | -3203.847% |
| Marizyme, Inc. | 18.56 Million USD | -115.978% |
| ContraFect Corporation | -6.02 Million USD | 765.533% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | -5797.794% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -29687.06% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | -3371.005% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | -1688.619% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | -628.931% |
| MultiCell Technologies, Inc. | 90.04 USD | -44541214.971% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 5564.06% |
| RVL Pharmaceuticals plc | 12.94 Million USD | -209.787% |
| EV Biologics, Inc. | 1.36 Million USD | -2831.714% |
| Q BioMed Inc. | 4.06 Million USD | -887.806% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | -31.259% |
| Neon Bloom, Inc. | 622.36 Thousand USD | -6343.978% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | -3879.792% |
| Biomind Labs Inc. | 711.4 Thousand USD | -5537.46% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 109.8 Million USD | 63.476% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | -213.159% |
| Skye Bioscience, Inc. | -5.72 Million USD | 800.966% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | -4562.066% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -28586.59% |
| Arch Therapeutics, Inc. | 5.64 Million USD | -610.028% |
| IMV Inc. | 7.67 Million USD | -422.846% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -201767.418% |
| Curative Biotechnology, Inc. | 2.2 Million USD | -1721.315% |
| GB Sciences, Inc. | 1.74 Million USD | -2195.235% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 21921.338% |
| HST Global, Inc. | 96.79 Thousand USD | -41333.781% |
| CSL Limited | 10.52 Billion USD | 99.619% |
| Halberd Corporation | 144.72 Thousand USD | -27611.942% |
| Enzolytics Inc. | 981.65 Thousand USD | -3985.443% |
| Resverlogix Corp. | 6.45 Million USD | -521.687% |
| Affymax, Inc. | -5.59 Million USD | 816.545% |
| SYBLEU INC | 473.71 Thousand USD | -8366.079% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 6058.35% |
| argenx SE | -2.02 Billion USD | 101.977% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 7.665% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 185.308% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -1380.646% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 553.681% |
| AVAX Technologies, Inc. | -5.9 Million USD | 779.376% |
| Zenith Capital Corp. | 10.06 Thousand USD | -398399.603% |
| Genscript Biotech Corporation | -1.06 Billion USD | 103.779% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | -19909.28% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | -1580.823% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | -24278.605% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 33.761% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | -1905.86% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | -2.57 Million USD | 1660.486% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -11049.259% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | -97.795% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 219037.657% |
| BioStem Technologies, Inc. | 4.47 Million USD | -796.8% |
| ONE Bio Corp. | 9.04 Million USD | -343.638% |
| Reve Technologies, Inc. | 201.25 Thousand USD | -19827.554% |
| Burzynski Research Institute, Inc. | -1310.00 USD | 3061550.382% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | -19347.96% |
| Agentix Corp. | 37.63 Thousand USD | -106474.367% |
| LadRx Corporation | -2.03 Million USD | 2069.34% |
| Cell Source, Inc. | 9.23 Million USD | -334.414% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 196616.072% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -6214.087% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -6214.087% |
| NovAccess Global Inc. | 2.17 Million USD | -1740.975% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | -467.178% |
| Itoco Inc. | 228.3 Thousand USD | -17466.413% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -29391.356% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | -709.058% |
| Kadimastem Ltd | -253.1 Thousand USD | 15945.39% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -9880.117% |
| CytoDyn Inc. | 20.26 Million USD | -97.932% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 6198708.964% |
| Mobile Lads Corp. | 484.23 Thousand USD | -8182.187% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 432809.633% |
| Qrons Inc. | 351.42 Thousand USD | -11312.043% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | -420.438% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 16166.421% |
| Rebus Holdings, Inc. | 305 Thousand USD | -13049.18% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | -799.816% |
| International Stem Cell Corporation | 2.59 Million USD | -1448.456% |
| Bioxytran, Inc. | 1.89 Million USD | -2011.997% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -64157.446% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -1738.92% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | -1067.88% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | -368.9% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | -5090.867% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 3308.4% |
| Neutra Corp. | 52.18 Thousand USD | -76748.64% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 1711.29% |
| PureTech Health plc | -167.19 Million USD | 123.987% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 16475.537% |
| IXICO plc | -4.44 Million USD | 1002.334% |
| IntelGenx Technologies Corp. | 13.21 Million USD | -203.389% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 26.884% |
| CSL Limited | 10.52 Billion USD | 99.619% |
| Cellectis S.A. | -43.81 Million USD | 191.524% |